Method of treating severe asthma
US-10420792-B2 · Sep 24, 2019 · US
Dosage form for treating severe asthma
US11129846B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11129846-B2 |
| Application number | US-201916539383-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 13, 2019 |
| Priority date | Feb 24, 2017 |
| Publication date | Sep 28, 2021 |
| Grant date | Sep 28, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
First claim
Opening claim text (preview).
We claim: 1. A dosage form comprising: a nucleic acid or an analog thereof able to decrease IRF5 expression in a patient in an amount effective to treat one or more symptoms of corticosteroid-insensitive asthma in a patient displaying a Th1 immune profile; a pharmaceutically acceptable carrier; and a metered-dose inhaler, sprayer, nebulizer, or insufflator for delivering a unit dose of the nucleic acid or the analog thereof, wherein the nucleic acid or the analog thereof is an antisense reagent or an interfering nucleic acid or analog thereof acting by RNA interference (RNAi). 2. The dosage form of claim 1 , wherein the nucleic acid or the analog thereof able to decrease IRF5 expression in the patient and the pharmaceutically-acceptable carrier is delivered from the metered-dose inhaler, sprayer, nebulizer, or insufflator as a liquid. 3. The dosage form of claim 1 , wherein the nucleic acid or the analog thereof able to decrease IRF5 expression in the patient and the pharmaceutically-acceptable carrier is delivered from the metered-dose inhaler, sprayer, nebulizer, or insufflator as a powder. 4. The dosage form of claim 1 , wherein the nucleic acid or the analog thereof able to decrease IRF5 expression in the patient and the pharmaceutically-acceptable carrier is delivered from the metered-dose inhaler, sprayer, nebulizer, or insufflator as an aerosol. 5. The dosage form of claim 1 , further comprising a corticosteroid. 6. The dosage form of claim 1 , wherein the interfering nucleic acid or analog thereof is an interfering microRNA (miRNA) reagent or an interfering small interfering RNA (siRNA) reagent. 7. A method of treating asthma in a patient, comprising reducing IRF5 activity to a level effective to treat one or more symptoms of asthma in a patient by administering, using the dosage form of claim 1 , the nucleic acid or the analog thereof able to decrease IRF5 expression in a patient and the pharmaceutically-acceptable carrier, in the amount effective to treat one or more symptoms of asthma in the patient. 8. A method of treating asthma in a patient, comprising reducing IRF5 activity to a level effective to treat one or more symptoms of asthma in a patient.
Assignees
Inventors
Classifications
substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone · CPC title
Antiasthmatics · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11129846B2 cover?
- Methods are provided for treating corticosteroid-resistant asthma in a patient, comprising decreasing Interferon Regulatory Factor 5 (IRF5) activity in the patient. Antisense or RNA interference reagents and methods can be used to decrease IRF5 activity in the patient.
- Who is the assignee on this patent?
- Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).